Journal: BMJ Open

Article Title: Assessing the efficacy, safety and utility of hybrid closed-loop glucose control compared with standard insulin therapy combined with continuous glucose monitoring in young people (≥16 years) and adults with cystic fibrosis-related diabetes (CL4P-CF study): protocol for an open-label, multicentre, randomised, two-arm and single-period parallel trial

doi: 10.1136/bmjopen-2025-111408

Figure Lengend Snippet: CamAPS FX HCL system. In the present study, we used the CamAPS FX HCL system comprising: YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland); Dexcom G6 real-time CGM (Dexcom, California, USA) or other approved compatible CGM; smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm (University of Cambridge, Cambridge, UK) and communicating wirelessly with the insulin pump and CGM transmitter; and cloud upload system to review CGM/insulin data (Glooko, Göteborg, Sweden). The closed-loop algorithm is hosted within the CamAPS FX app which communicates wirelessly with the CGM device and insulin pump. CGM, continuous glucose monitoring; HCL, hybrid closed-loop.

Article Snippet: Participants will use the CamAPS FX HCL system ( ) comprising Dexcom G6 CGM (Dexcom, California, USA), YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland) and the mylife CamAPS FX app (CamDiab, Cambridge, UK) on a standard smartphone.

Techniques: Control

Journal: Journal of the Endocrine Society

Article Title: Continuous Glucose Monitoring in Patients With Postbariatric Hypoglycemia: Effect on Hypoglycemia and Quality of Life

doi: 10.1210/jendso/bvaf106

Figure Lengend Snippet: Study design overview. Participants were first screened, randomized, and trained in CGM use. Subjects were then assigned to begin with either a 10-day unblinded CGM (Dexcom G6) or 10-day blinded CGM (Dexcom G6 Pro) period. Each monitoring phase was followed by completion of the Hypoglycemia Fear Survey-II (HFS-II), an event diary, and training (if applicable) with a new CGM device. All participants crossed over to the alternate CGM modality for another 10-day period. The study concluded with repeated HFS-II assessments, event diary entries, and CGM data download. Blinded CGM data (Dexcom G6 Pro) was used for all outcome analyses to ensure consistency.

Article Snippet: Participants assigned to the unblinded period were instructed on how to view their Dexcom G6 glucose values in real time using either the Dexcom app or a Dexcom receiver.

Techniques: